Skip to content
Screener

Emergent Biosolutions EBS Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$266.8M+13.8%
SIGA Technologies logo
SIGA TechnologiesSIGA
$439.4K-58.8%
AMP
Amphastar PharmaceuticalsAMPH
$27.4M
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$1.31M
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$4.17M-22.4%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$4.71M-7.6%

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$229.19M-47.4%
Enterprise value$676.49M-19.5%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
LeasesClassificationJune 30, 2026December 31, 2025
Operating lease right-of-use assetsOther assets$5.8$10.6
Operating lease liabilities, current portionOther current liabilities$1.5$2.4
Operating lease liabilitiesOther liabilities4.99.2
Total operating lease liabilities$6.4$11.6
Operating leases:
Weighted average remaining lease term (years)5.15.2
Weighted average discount rate7.9%6.5%

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's operating lease liabilities (total)?
Emergent Biosolutions (EBS) reported operating lease liabilities (total) of $6.4M in Q2 2026.
How has Emergent Biosolutions's operating lease liabilities (total) changed year-over-year?
Emergent Biosolutions's operating lease liabilities (total) decreased by 22.9% year-over-year, from $8.3M to $6.4M.
What is the long-term trend for Emergent Biosolutions's operating lease liabilities (total)?
Over 5 years (2020 to 2025), Emergent Biosolutions's operating lease liabilities (total) has grown at a -19.0% compound annual growth rate (CAGR), from $33.2M to $11.6M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Emergent Biosolutions's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude